Company Overview - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [3] - The company's lead product candidate, certepetide, is designed to activate a novel uptake pathway for more effective targeting and penetration of solid tumors by anti-cancer drugs [3] - Lisata has established significant commercial and R&D partnerships based on its CendR Platform technology [3] Upcoming Presentation - David J. Mazzo, Ph.D., President and CEO of Lisata, will present a corporate overview at the Investival Showcase USA on March 11, 2025, at 11:30 a.m. Eastern Time [2] - The conference will take place in Miami, Florida, on March 10-11, 2025 [1] Future Expectations - The company anticipates announcing numerous milestones over the next 1.5 years and believes its projected capital will fund operations into the second quarter of 2026 [3] - This funding will encompass expected data milestones from ongoing and planned clinical trials [3]
Lisata Therapeutics to Present at the Investival Showcase USA